daily oral glp-1 receptor agonist orforglipron for adults with obesity 272 participants randomized. Baseline Mean body weight : 108.7 kg Mean weight loss at week 26: −8.6% to −12.6% dose cohorts −2.0% in the placebo group. ➡️Daily orforglipron, a nonpeptide Oral GLP-1 Orforglipron Is Approved

Description

10.1056/NEJMoa1501352 [DOI] [PubMed] [Google Scholar] 65.Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al

Footnotes Disclosure: SK has a sponsored research agreement with Janssen Pharmaceuticals Inc., serves on a scientific advisory board for Altimmune, and has served as a consultant for Eli Lilly and B2M Medical

The Lancet, 397 ,

Innovator Novo Nordisk launched its semaglutide brands Wegovy and Ozempic in India last year, racing to capture early market share before losing patent exclusivity on 20 March 2026